CompanyAAVXF ABVXNasdaq, OTCParis

Abivax S.A.

Abivax develops small-molecule therapeutics that modulate immune regulation for chronic inflammatory diseases.

SEC EDGAR ClinicalTrials.gov edge.media-server.com

6-KSep 21Latest SEC filing, period to Jun 30

Sep 21Latest story

September 2026

Abivax reports H1 2026 results, says NDA filing for obefazimod still on track for Q4

Sep 21Quarterly updateAbivax S.A.obefazimod

Abivax posts Phase 3 results for obefazimod in ulcerative colitis across ABTECT-1 and ABTECT-2

Sep 10Weekly roundup, 2 itemsAbivax S.A.obefazimod

July 2026

Abivax prices $800 million ADS offering, cites Phase 3 UC maintenance data

Jul 2FinancingAbivax S.A.obefazimod

June 2026

Abivax reports Part 2 maintenance data for obefazimod in ulcerative colitis

Jun 29Clinical readoutAbivax S.A.obefazimod